|
Traditional risk factors in systemic sclerosis patients and healthy controls |
|||
| Characteristic |
Patients (n = 49) |
Controls (n = 32) |
P value |
|
|
|||
| Age, years |
55.4 ± 11.6 |
50.9 ± 10.1 |
0.078 |
| Male gender, number (percentage) |
8 (16%) |
3 (9.4%) |
0.513 |
| Body mass index, kg/m2 |
23.7 ± 2.9 |
24.0 ± 2.9 |
0.582 |
| Smoking |
|||
| Pack years for smokers, number (percentage) |
3 (6%) |
2 (6.5%) |
1.000 |
| Median (range) |
20 (1–48) |
10 (6–14) |
|
| Diabetes mellitus, number (percentage) |
2 (4%) |
0 |
0.523 |
| Hypertension treated with antihypertensive agents, number (percentage) |
12 (24%) |
2 (6%) |
0.120 |
| Blood pressure, mm Hg |
|||
| Systolic |
120 (110–135) |
120 (110–125) |
0.409 |
| Diastolic |
75 (70–80) |
75 (70–80) |
0.379 |
| Cholesterol, mmol/L |
|||
| Total |
5.22 ± 1.00 |
5.53 ± 1.06 |
0.217 |
| Low-density lipoprotein |
3.02 ± 0.85 |
3.06 ± 1.08 |
0.871 |
| High-density lipoprotein |
1.40 (1.23–1.80) |
1.68 (1.48–1.89) |
0.027 |
| Triglycerides, mmol/L |
1.36 (1.16–2.14) |
1.17 (0.77–1.67) |
0.030 |
| Lipid-lowering drugs, number (percentage) |
7 (14%) |
0 |
0.038 |
| Simvastatin, number (mean dose in milligrams) |
4 (20) |
0 |
|
| Atorvastatin, number (mean dose in milligrams) |
2 (25) |
0 |
|
| Rosuvastatin, number (mean dose in milligrams) |
1 (10) |
0 |
|
| Family history of cardiovascular disease, number (percentage) |
10 (20%) |
5 (16%) |
0.603 |
| Cardiovascular history, number (percentage) |
4 (8%) |
0 |
0.149 |
| Cardiovascular |
1 |
||
| Cerebrovascular |
1 |
||
| Peripheral vascular disease |
2 |
||
| C-reactive protein, mg/L |
3.5 (1.6–7.0) |
0.8 (0.3–2.0) |
< 0.001 |
|
Unless stated otherwise, data are expressed as mean ± standard deviation when normally distributed and as median (interquartile range) when non-normally distributed. | |||
Hettema et al. Arthritis Research & Therapy 2008 10:R49 doi:10.1186/ar2408 |
|||